Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2000 4
2001 2
2002 1
2003 1
2004 1
2005 1
2006 1
2007 3
2008 2
2014 1
2015 2
2019 1
2020 2
2021 2
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. Among authors: korolkiewicz rp. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, Bartos P, Chovanec J, Valha P, Pluta M, Novotny Z, Spacek J, Melichar B, Kieszko D, Fucikova J, Hrnciarova T, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Rob L, et al. Among authors: korolkiewicz rp. J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190. J Immunother Cancer. 2022. PMID: 34992091 Free PMC article. Clinical Trial.
Recreational abuse with benzydamine hydrochloride (tantum rosa).
Anand JS, Glebocka ML, Korolkiewicz RP. Anand JS, et al. Among authors: korolkiewicz rp. Clin Toxicol (Phila). 2007;45(2):198-9. doi: 10.1080/15563650600981210. Clin Toxicol (Phila). 2007. PMID: 17364645 No abstract available.
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.
Zemanova M, Cernovska M, Havel L, Bartek T, Lukesova S, Jakesova J, Vanasek J, Reiterer P, Kultan J, Andrasina I, Siskova L, Koubkova L, Skrickova J, Salajka F, Pesek M, Klepetko P, Beniak J, Fricke H, Kadlecova P, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Zemanova M, et al. Among authors: korolkiewicz rp. Cancer Treat Res Commun. 2021;28:100427. doi: 10.1016/j.ctarc.2021.100427. Epub 2021 Jun 26. Cancer Treat Res Commun. 2021. PMID: 34284344 Free article. Clinical Trial.
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S, Libretto SE, Sprenger T, Radue EW. Constantinescu CS, et al. Among authors: korolkiewicz rp. Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e117. doi: 10.1212/NXI.0000000000000117. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26185773 Free PMC article.
26 results